| name | es-cushing-targeted-therapies-ectopic-acth-syndrome |
| description | This skill suggests targeted therapies (somatostatin analogs or tyrosine kinase inhibitors) to treat ectopic ACTH syndrome when ectopic ACTH secretion is confirmed or strongly suspected. Use when triggers include occult or metastatic ectopic ACTH secretion, very severe ACTH‑dependent disease uncontrolled by medical therapy, or when surgery is not possible or noncurative. |
Targeted Therapies to Treat Ectopic ACTH Syndrome
STEP 1 — Gather Information
Confirm ectopic ACTH secretion: serum ACTH >20 pg/mL with unsuppressible cortisol, low‑dose dexamethasone non‑suppression, and no pituitary lesion on MRI. Perform inferior petrosal sinus sampling if pituitary source uncertain. Obtain cross‑sectional imaging (CT chest/abdomen/pelvis, somatostatin receptor PET/CT or DOTATATE PET) to localize tumor and assess resectability. Review prior medical therapy and comorbidities.
Action: Proceed to Rule In/Rule Out.
STEP 2 — Rule In / Rule Out
Rule In: Elevated ACTH with cortisol excess and no pituitary source confirms ectopic ACTH syndrome.
Rule Out: If ACTH is normal/pituitary lesion identified on MRI or petrosal sampling, consider Cushing’s disease or adrenal etiology and redirect to appropriate pathway.
Action: If ectopic ACTH confirmed, advance to classification; otherwise reconsider diagnosis.
STEP 3 — Classify or Stratify
Stratify by tumor type and resectability:
- Occult or metastatic ectopic ACTH‑secreting tumor (non‑MTC) → consider somatostatin analog.
- Ectopic ACTH from metastatic medullary thyroid carcinoma → consider tyrosine kinase inhibitor.
- Tumor resectable → prioritize surgical referral over medical targeted therapy.
Action: Select appropriate targeted therapy class based on tumor type.
STEP 4 — Decide
For occult/metastatic non‑MTC ectopic ACTH: initiate pasireotide 600–900 µg SC twice daily (or lanreotide/octreotide per labeling).
For metastatic MTC‑driven ectopic ACTH: start vandetanib 300 mg PO daily (or sorafenib 400 mg PO twice daily).
If patient cannot take oral agents or has life‑threatening hypercortisolism, use etomidate infusion as a bridge while arranging definitive therapy.
Action: Initiate the chosen targeted therapy and schedule baseline labs (LFTs, ECG, glucose, cortisol) and follow‑up imaging.
Clinical Guardrails / Mimics / Pitfalls
Monitor pasireotide‑treated patients for hyperglycemia (check fasting glucose q1‑2w), QT prolongation, and cholelithiasis; avoid in patients with uncontrolled diabetes.
Vandetanib/sorafenib require ECG and LFT monitoring; hold for QTc >480 ms or grade ≥3 hepatic toxicity.
Do not rely solely on targeted therapy if the tumor is surgically resectable; surgery remains first‑line when feasible.
Be aware that somatostatin analogs may control cortisol without tumor shrinkage; lack of size does not preclude continued use if biochemical control is achieved.
Avoid delaying definitive surgery or radiotherapy when a curative option exists.
Concrete Clinical Example
A 58‑year‑old woman with metastatic medullary thyroid carcinoma presented with ectopic ACTH‑driven Cushing’s syndrome (ACTH 210 pg/mL, UFC 450 µg/24h) unresponsive to ketoconazole. Vandetanib 300 mg daily was started; after 4 weeks UFC normalized to 45 µg/24h, blood pressure improved, and hyperglycemia resolved. Therapy continued with monthly ECG and LFTs; no dose adjustments needed.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI:10.1210/jc.2015-1818
